 Research analysts at Cowen assumed coverage on shares of Aimmune Therapeutics NASDAQ:AIMT in a research note issued on Monday, Briefing.com Automated Import reports. The brokerage set an outperform rating and a 35.00 price target on the biotechnology companys stock. Cowens target price points to a potential upside of 123.21 from the stocks current price. AIMT ... 